Jazz Pharmaceuticals (JAZZ) – Analysts’ Recent Ratings Updates

Jazz Pharmaceuticals (NASDAQ: JAZZ) recently received a number of ratings updates from brokerages and research firms:

• 8/11/2026 – Jazz Pharmaceuticals had its price target raised by Morgan Stanley from $280.00 to $283.00. They now have an “overweight” rating on the stock.
• 8/4/2026 – Jazz Pharmaceuticals was upgraded by Weiss Ratings from “hold (c-)” to “buy (b-)”.
• 8/4/2026 – Jazz Pharmaceuticals had its “buy” rating reaffirmed by Deutsche Bank Aktiengesellschaft. They now have a $287.00 price target on the stock.
• 8/4/2026 – Jazz Pharmaceuticals had its price target raised by TD Cowen from $275.00 to $300.00. They now have a “buy” rating on the stock.
• 8/4/2026 – Jazz Pharmaceuticals was given a new $264.00 price target by Truist Financial Corporation. They now have a “buy” rating on the stock.
• 8/4/2026 – Jazz Pharmaceuticals had its “buy” rating reaffirmed by UBS Group AG. They now have a $315.00 price target on the stock.
• 8/4/2026 – Jazz Pharmaceuticals had its price target raised by Wells Fargo & Company from $285.00 to $300.00. They now have an “overweight” rating on the stock.
• 8/4/2026 – Jazz Pharmaceuticals was given a new $275.00 price target by Stifel Nicolaus.
• 8/4/2026 – Jazz Pharmaceuticals had its price target raised by Piper Sandler from $301.00 to $310.00. They now have an “overweight” rating on the stock.
• 8/4/2026 – Jazz Pharmaceuticals had its price target raised by Barclays PLC from $260.00 to $270.00. They now have an “overweight” rating on the stock.
• 8/4/2026 – Jazz Pharmaceuticals had its price target raised by JPMorgan Chase & Co. from $265.00 to $276.00. They now have an “overweight” rating on the stock.
• 8/4/2026 – Jazz Pharmaceuticals had its price target raised by Morgan Stanley from $245.00 to $280.00. They now have an “overweight” rating on the stock.
• 8/4/2026 – Jazz Pharmaceuticals had its price target raised by Robert W. Baird from $252.00 to $280.00. They now have an “outperform” rating on the stock.
• 8/4/2026 – Jazz Pharmaceuticals had its price target raised by Needham & Company LLC from $282.00 to $292.00. They now have a “buy” rating on the stock.
• 7/20/2026 – Jazz Pharmaceuticals had its price target raised by Needham & Company LLC from $255.00 to $282.00. They now have a “buy” rating on the stock.
• 7/16/2026 – Jazz Pharmaceuticals is now covered by Canaccord Genuity Group Inc.. They set a “buy” rating and a $290.00 price target on the stock.
• 7/16/2026 – Jazz Pharmaceuticals was upgraded by Canaccord Genuity Group Inc. to “strong-buy”.
• 7/14/2026 – Jazz Pharmaceuticals had its price target raised by Wells Fargo & Company from $265.00 to $285.00. They now have an “overweight” rating on the stock.
• 7/14/2026 – Jazz Pharmaceuticals had its price target raised by Barclays PLC from $253.00 to $260.00. They now have an “overweight” rating on the stock.
• 7/9/2026 – Jazz Pharmaceuticals had its price target raised by Deutsche Bank Aktiengesellschaft from $250.00 to $270.00. They now have a “buy” rating on the stock.
• 7/7/2026 – Jazz Pharmaceuticals had its price target lowered by Truist Financial Corporation from $256.00 to $254.00. They now have a “buy” rating on the stock.
• 6/29/2026 – Jazz Pharmaceuticals was upgraded by Weiss Ratings from “sell (d+)” to “hold (c-)”.

Insider Buying and Selling at Jazz Pharmaceuticals

In other news, Director Mark Douglas Smith sold 1,157 shares of the company’s stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $230.55, for a total value of $266,746.35. Following the transaction, the director owned 9,680 shares in the company, valued at approximately $2,231,724. This represents a 10.68% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Heather Ann Mcsharry sold 2,000 shares of the stock in a transaction that occurred on Friday, May 22nd. The shares were sold at an average price of $241.00, for a total transaction of $482,000.00. Following the sale, the director owned 18,449 shares in the company, valued at approximately $4,446,209. The trade was a 9.78% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 19,098 shares of company stock worth $4,649,786 in the last 90 days. Insiders own 4.10% of the company’s stock.

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.